内科

目的探讨依折麦布联合瑞舒伐他汀在急性冠脉综合征（ACS）患者经皮冠状动脉介入（PCI）术后的应用效果。方法选择2018年9月至2019年4月收治的ACS患者70例为研究对象，均于急诊行PCI术治疗。将纳入的研究对象随机分为对照组和观察组，每组35例。对照组患者PCI术后行瑞舒伐他汀治疗，观察组患者给予依折麦布联合瑞舒伐他汀治疗，两组均治疗12个月。比较两组患者治疗前后的血清总胆固醇、三酰甘油、低密度脂蛋白胆固醇（LDL-C）、高密度脂蛋白胆固醇（HDL-C）、内皮素-1、脂蛋白相关磷脂酶A2（Lp-PLA2）水平；比较两组患者治疗12个月后的冠脉支架内再狭窄率、治疗期间不良反应发生情况，以及随访1年期间心血管不良事件的发生情况。结果治疗12个月后，观察组患者的血清总胆固醇、三酰甘油、LDL-C、内皮素-1、Lp-PLA2水平均低于对照组（均P＜0.05）；两组患者的血清HDL-C水平差异无统计学意义（P＞0.05）。观察组患者治疗12个月后的冠脉支架内再狭窄率（5.71%）低于对照组（22.86%）（P＜0.05）。两组患者治疗期间均无不良反应发生。观察组患者随访1年期间心血管不良事件发生率（11.43%）低于对照组（34.29%）（P＜0.05）。结论依折麦布联合瑞舒伐他汀治疗能够更好地改善ACS患者PCI术后的血脂水平，改善血管内皮功能，减少冠脉支架内再狭窄和心血管不良事件发生，值得临床推广使用。

ObjectiveTo investigate the application effect of ezetimibe combined with rosuvastatin in patients with acute coronary syndrome (ACS) after percutaneous coronary intervention (PCI). MethodsA total of 70 ACS patients admitted from September 2018 to April 2019 and received PCI in the emergency department were selected as research subjects, and they were randomly divided into a control group or an observation group, with 35 cases in each group. After the PCI, the control group patients were treated with rosuvastatin, while the observation group patients were treated with the combination of ezetimibe and rosuvastatin. Both groups received 12 months of treatment. The followings were compared between the two groups, including the serum total cholesterol, triacylglycerol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), endothelin-1, and lipoprotein-associated phospholipase A2 (Lp-PLA2) levels before and after the treatment, as well as the coronary in-stent restenosis rate after the 12-month treatment, the occurrence of adverse reactions during the treatment, and the occurrence of adverse cardiovascular events during the 1-year follow-up. ResultsAfter the 12-month treatment, the observation group patients had lower serum total cholesterol, triacylglycerol, LDL-C, endothelin-1, and Lp-PLA2 levels as compared with the control group patients (all P＜0.05); while the serum HDL-C level between the two groups showed no statistically significant difference (P＞0.05). After the 12-month treatment, the observation group patients had a lower coronary in-stent restenosis rate than the control group patients(5.71% vs. 22.86%, P＜0.05). No adverse reaction happened in the two groups during the treatment. The incidence of adverse cardiovascular events in the observation group was lower than that in the control group (11.43% vs. 34.29%, P＜0.05). ConclusionFor ACS patients after PCI, ezetimibe combined with rosuvastatin can better improve their blood lipid levels and vascular endothelial function, reduce the incidence of coronary in-stent restenosis and adverse cardiovascular events, which is worthy of clinical promotion.